CClinicalTrials.gg
CompletedNCT04320004Updated Sep 22, 2021

Evaluation of a Medication Disposal Program in Primary Care

An interventional study of Education and Education with Reminder in Opioid-Related Disorders, sponsored by Geisinger Clinic. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2021-09-22.

Sponsored by Geisinger Clinic · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
1,159
Allocation
Randomized
Sex
All
01

Study summary

Evidence from recent trials primarily in the post-surgical patient population prescribed opioids for acute pain suggest patients more often properly dispose of unused opioids if instructed by a healthcare professional, if provided education on proper storage and disposal, and provided a physical medication disposal product (e.g. mail back bags). It is not clear how this evidence applied to patients in primary care will be readily adopted and sustained by practices and if the effectiveness will be comparable to that seen in other more controlled studies, largely limited to the surgical population. The objective of this trial is to evaluate a multifaceted program for safe medication disposal in primary care. Interventions include real-time best practice reminders to providers, educational materials mailed to patients, disposal mail-back bags supplied to patients and reminder phone calls. Proper medication disposal after 30 days following order will be assessed by telephone survey.

Our aims are to:

  1. Evaluate a targeted intervention on patient's newly prescribed opioids within primary care.
  2. Determine factors that influence patient action to remove unused opioid medications from the home.
Read the detailed description

Prospective studies affirm that education and advice from providers to dispose of unused medications modestly improves medication disposal rates. Two recently published randomized controlled trials demonstrate improved disposal rates when a system for medication disposal, namely a medication disposal bag (e.g. return envelope or activated charcoal) were supplied to patients or caregivers. The impact of education and physical disposal mechanism inferred a greater magnitude of effect than education alone.

Research Design The investigators will use a cluster-randomized stepped-wedge design, using clinics as clusters (i.e., all clinics participate in all arms, but not all at the same time) to compare two main interventions (education only vs. education + mail-back bag). In addition, the investigators will randomize patients in both intervention arms to receive or not to receive an added telephone reminder call through interactive voice response (IVR). The primary outcome of the study, medication disposal actions taken by the patient, will be assessed by a telephone survey.

Study Population The investigators will enroll patients newly prescribed an opioid medication within one of the participating clinics. For patients younger than 18 years old, the investigators will follow clinic procedures for the engagement of parents or guardians; the investigators anticipate that management of medications in this population is largely handled by the guardian or parent and therefore these patients are of key interest when studying proper medication storage and disposal.

Interventions

(1) baseline; (2) education at the clinic level; (3) educational materials mailed to the patient's home; (4) mail back bags mailed to patient's homes and (5) IVR reminder calls

The study will enroll 13 clinics into the intervention with one clinic serving as an initial pilot. Feasibility and troubleshooting of the interventions will be tested within the pilot clinic; the pilot clinic will not be included within the final analysis.

All clinics will initially be assessed at baseline (usual care) followed by education only for approximately 3 months until the targeted quota of patients for the clinic is achieved. Following this attainment, new patients will begin receiving mail-back bags in addition to the education for the remainder of the enrollment period, in order to create the two main patient groups. Approximately 50% of patients during both education only and mail back bag stages of enrollment will be selected for IVR reminder calls, using a random number generator method.

Evaluation of safe medication disposal at 30-45 days post initial opioid prescription will be conducted through a telephone survey.

02

Conditions studied

  • Opioid-Related Disorders

Keywords

  • opioid
  • medication disposal
  • medication safety
03

In context

Opioid-Related Disorders

1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

This study's enrollment of 1,159 is above the median of 63 across 1,123 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

Geisinger Clinic is the lead sponsor of 125 studies on the registry; 21 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Any patient receiving a new opioid prescription in a face-to-face or telehealth encounter in select Community Medicine Service Line practices.
  • "New opioid prescription" is defined as a prescription for an opioid medication, Categories II-V (not anti-tussive) to a patient who has no opioid on current medication profile and no opioid prescriptions in the previous 3 months.
  • Preferred language, as documented in the electronic health record (EHR), is English.
  • Providers in participating primary care practices who receive the Best Practice Alert (BPA) for eligible patients.

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,159 participants (actual)

Study arms

  • No intervention
    Baseline

    Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a "silent best practice alert (BPA)" in these clinics. This "Silent BPA" is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list.

  • Active comparator
    Education Intervention

    If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.

    Behavioral: Education

  • Active comparator
    Education Intervention with Reminder

    This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.

    Behavioral: Education with Reminder

  • Active comparator
    Education + Disposal Bag Intervention

    If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.

    Behavioral: Education + Disposal Bag

  • Active comparator
    Education + Disposal Bag Intervention with Reminder

    This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.

    Behavioral: Education + Disposal Bag with Reminder

Interventions

  • BehavioralEducation

    Subject receives education

  • BehavioralEducation with Reminder

    Subject receives education with reminder

  • BehavioralEducation + Disposal Bag

    Subject receives education and disposal bag

  • BehavioralEducation + Disposal Bag with Reminder

    Subject receives education + disposal bag with reminder

06

What researchers measure

Primary outcomes

  1. Disposal of unused opioid following new opioid prescription

    Proportion of patients with unused opioid medication who dispose opioid as assessed by telephone survey

    Time frame: 30-45 days post new opioid prescription

Secondary outcomes

  1. Patient satisfaction with medication mail back disposal bag

    Patient satisfaction with mail-back bag, as assessed by telephone survey

    Time frame: 30-45 days post new opioid prescription

  2. Second prescription of opioid within 60 days post new opioid prescription

    Prescription order for second opioid prescription as assessed by electronic health record

    Time frame: 60 days post new opioid prescription

07

Study locations

1 site
  • Geisinger
    Danville, Pennsylvania 17822, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04320004
Lead sponsor
Geisinger Clinic
Responsible party
Eric Wright (Professor, Geisinger Clinic) — Principal investigator
First posted
Mar 24, 2020
Start date
May 1, 2020
Primary completion
May 6, 2021
Completion
Jun 30, 2021
Last update
Sep 22, 2021

Study contacts

Eric Wright, PharmD,MPH
principal investigator · Geisinger Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion